

This article was downloaded by:

On: 26 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



## Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

## Synthesis of Oligonucleotide Prodrugs Bearing *N*-Acetyl Nucleobases

J. -C. Brès<sup>a</sup>; J. -L. Imbach<sup>a</sup>; F. Morvan<sup>ab</sup>

<sup>a</sup> Laboratoire de Chimie Organique Biomoléculaire de Synthèse, Université de Montpellier II, Montpellier Cedex, France <sup>b</sup> Université de Montpellier II, Montpellier Cedex 5, France

Online publication date: 09 August 2003

**To cite this Article** Brès, J. -C. , Imbach, J. -L. and Morvan, F.(2003) 'Synthesis of Oligonucleotide Prodrugs Bearing *N*-Acetyl Nucleobases', *Nucleosides, Nucleotides and Nucleic Acids*, 22: 5, 1243 — 1245

**To link to this Article:** DOI: 10.1081/NCN-120022846

**URL:** <http://dx.doi.org/10.1081/NCN-120022846>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

## Synthesis of Oligonucleotide Prodrugs Bearing *N*-Acetyl Nucleobases

J.-C. Brès, J.-L. Imbach, and F. Morvan\*

Laboratoire de Chimie Organique Biomoléculaire de Synthèse,  
Université de Montpellier II, UMR 5625 CNRS-UMII,  
Montpellier Cedex, France

### ABSTRACT

*N*-Acetyl oligonucleotides and their prodrugs were synthesized on photolabile solid support. T<sub>m</sub> studies showed a decrease of hybridization for *N*-acetyl A and G and an increase for *N*-acetyl C. In cells extract, acetyl groups were hydrolysed.


**Key Words:** Protecting group; Enzymolabile; Base-sensitive.

We have been applying a prodrug concept to oligonucleotides (pro-oligos), to overcome their instability in biological fluids and enhance their low cellular uptake.<sup>[1]</sup> In pro-oligos, the majority of phosphate are transitorily masked with the carboxy-esterase-labile S-Acetyl-2-ThioEthyl (Me-SATE) group. To validate this approach we have shown on pro-thymidine models that there are efficiently and rapidly taken up by cells<sup>[2]</sup> and the Me-SATE groups are hydrolysed in cells extract.<sup>[3]</sup>

To synthesize hetero pro-oligos, we evaluated the acetyl group<sup>[4]</sup> as a permanent group of the nucleobases.

\*Correspondence: F. Morvan, Université de Montpellier II, CC008, Place E. Bataillon, F-34095 Montpellier Cedex 5, France; Fax: +33 4 6704 2029; E-mail: morvan@univ-montp2.fr.





**Figure 1.** HPLC and MALDI-TOF MS of the *N*-acetyl GCGACCCAACAC pro-oligo bearing 8 Me-SATE and 4 diester linkages targeted against the IRES site.

First, the 5'-DMTr of A<sup>Ac</sup>, C<sup>Ac</sup>, G<sup>Ac</sup> and T were synthesized and converted into the corresponding Me-SATE phosphoramidite and H-phosphonate derivatives. Then, we synthesized three *N*-acetylated dodecanucleotide models each bearing 4 of one *N*-acetylated nucleobases and 8 thymidines. We noticed some deacetylation on A and C during their work-up while on G acetyls were stable. T<sub>m</sub> studies showed a slight increase for oligo bearing C<sup>Ac</sup> ( $\approx +1^{\circ}\text{C}/\text{mod}$ ) and a dramatic decrease for oligos bearing G<sup>Ac</sup> and A<sup>Ac</sup> ( $-7.5$  and  $\approx -7^{\circ}\text{C}/\text{mod}$  respectively).

Incubation of these *N*-acetyl oligos in CEM cells extract showed by MALDI-TOF mass spectrometry that the acetyl groups were rapidly hydrolysed on A and C while on G the hydrolysis was slower.

Since acetyl groups could be removed by an enzymatic way, we decided to use them on Me-SATE pro-oligos. Two *N*-Acyl Me-SATE pro-oligos targeted against the internal ribosome entry sequence (IRES) of HCV of a plasmid construct were synthesized using the phosphoramidite and H-phosphonate chemistries on a photolabile solid support. These pro-oligos presented the same sequence (GCGACCCAACAC) but a different number of Me-SATE on each wing of 3 and 4 with a central window of phosphodiester linkages of 6 and 4 respectively, in order to gain molecules of different lipophilicity. Indeed, we have shown that lipophilicity is an important factor for their uptake, with a better uptake when the lipophilicity increased. After synthesis the both *N*-acyl Me-SATE pro-oligos were purified by reverse phase C<sub>18</sub> HPLC and characterized by MALDI-TOF MS (Fig. 1). The MALDI-TOF spectra showed a slight deacetylation of the pro-oligo with signals spaced by 42 Da corresponding to a loss of one acetyl group (Fig. 1B).

Thanks to *N*-acetyl protection, hetero MeSATE pro-oligos were synthesized. In a near future their capacity to inhibit gene expression would be evaluated.

#### ACKNOWLEDGMENT

This work was supported by grant from "Association pour le Recherche contre le Cancer" (ARC). JCB thanks the ARC for the award of a research studentship.

## REFERENCES

1. Morvan, F.; Vasseur, J.-J.; Vivès, E.; Rayner, B.; Imbach, J.-L. The oligonucleotide prodrug approach: The pro-oligonucleotides. In *Pharmaceutical aspects of oligonucleotides*; Taylor & Francis: London, 2000; 79–97.
2. Bologna, J.C.; Vives, E.; Imbach, J.L.; Morvan, F. Uptake and quantification of intracellular concentration of lipophilic pro-oligonucleotides in HeLa cells. *Anti-sense Nucleic Acid Drug Dev* **2002**, *12*, 33–41.
3. Brès, J.C.; Morvan, F.; Lefebvre, I.; Vasseur, J.J.; Pompon, A.; Imbach, J.L. Kinetics study of the biotransformation of an oligonucleotide prodrug in cells extract by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. *J. Chrom. B* **2001**, *753*, 123–130.
4. Wada, T.; Kobori, A.; Kawahara, S.; Sekine, M. Synthesis and properties of oligodeoxyribonucleotides containing 4-*N*-acetylcytosine bases. *Tetrahedron Lett.* **1998**, *39*, 6907–6910.



